CG Oncology, Inc.'s promising bladder cancer therapy has strong clinical results, competitive CR rates, and a $69 target ...

CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright ...

CG Oncology, Inc. (CGON) closed the last trading session at $26.42, gaining 2.2% over the past four weeks, but there could be ...

In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price ...

March 28, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

In this article, we are going to take a look at where CG Oncology, Inc. (NASDAQ:CGON) stands against other best IPO stocks to buy in 2025. On February 25, Hamilton Lane co-CEO Erik Hirsch joined ...

Across the recent three months, 4 analysts have shared their insights on CG Oncology CGON -2.73% Get Free Report , expressing a variety of opinions spanning from bullish to bearish. Summarizing their ...

CG Oncology, Inc. (CGON) closed the last trading session at $26.42, gaining 2.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...